CG Oncology Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
CGON$75.99+17.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(In thousands, except share and per share amounts)
| September 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets · (unaudited) | ||
| Current assets: | ||
| Cash and cash equivalents | $43,411 | $8,266 |
| Marketable securities | 497,299 | 179,408 |
| Prepaid expenses and other current assets | 11,233 | 6,358 |
| Accounts receivable - other | 137 | 92 |
| Total current assets | 552,080 | 194,124 |
| Property and equipment, net | 63 | 69 |
| Operating lease right-of-use assets | 275 | 422 |
| Other assets | 53 | 19 |
| Deferred offering costs | — | 4,667 |
| Total assets | $552,471 | $199,301 |
| Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | $4,076 | $3,242 |
| Success fee liability, current portion | — | 352 |
| Operating lease liabilities, current portion | 225 | 217 |
| Accrued expenses and other current liabilities | 11,329 | 10,443 |
| Total current liabilities | 15,630 | 14,254 |
| Success fee liability, non-current | — | 13 |
| Operating lease liabilities, net of current portion | 71 | 244 |
| Total liabilities | 15,701 | 14,511 |
| Commitments and contingencies (Note 5) | ||
| Redeemable convertible preferred stock: | ||
| Series A-1 redeemable convertible preferred stock, $0.0001 par value per share; zero and 5,075,000 shares authorized, issued and outstanding as of September 30, 2024 and December 31, 2023, respectively; liquidation value of $0 and $3,570 as of September 30, 2024 and December 31, 2023, respectively | — | 3,570 |
| Series B redeemable convertible preferred stock, $0.0001 par value per share; zero and 11,973,000 shares authorized, issued and outstanding as of September 30, 2024 and December 31, 2023; liquidation value of $0 and $10,000 as of September 30, 2024 and December 31, 2023, respectively | — | 10,000 |
| Series C redeemable convertible preferred stock, $0.0001 par value per share; zero and 73,598,283 shares authorized, issued and outstanding as of September 30, 2024 and December 31, 2023, respectively; liquidation value of $0 and $22,000 as of September 30, 2024 and December 31, 2023, respectively | — | 22,000 |
| Series D redeemable convertible preferred stock, $0.0001 par value per share; zero and 53,271,754 shares authorized, issued and outstanding as of September 30, 2024 and December 31, 2023, respectively; liquidation value of $0 and $47,300 as of September 30, 2024 and December 31, 2023, respectively | — | 47,300 |
| Series E redeemable convertible preferred stock, $0.0001 par value per share; zero and 112,422,700 shares authorized, issued and outstanding as of September 30, 2024 and December 31, 2023, respectively; liquidation value of $0 and $120,000 as of September 30, 2024 and December 31, 2023, respectively | — | 120,000 |
| Series F redeemable convertible preferred stock, $0.0001 par value per share; zero and 81,587,937 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively; liquidation value of zero and $105,020 as of September 30, 2024 and December 31, 2023, respectively | — | 105,020 |
| Stockholders’ equity (deficit): | ||
| Common stock, $0.0001 par value per share; 700,000,000 and 493,530,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; 67,537,858 and 5,222,283 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 7 | — |
| Additional paid-in capital | 722,946 | 6,842 |
| Accumulated deficit | (186,183) | (129,942) |
| Total stockholders' equity (deficit) | 536,770 | (123,100) |
| Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | $552,471 | $199,301 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.